CD40 LIGAND AS ADJUVANT FOR RAISING PROTECTIVE ANTI-HIV AB BY DNA/MVA VACCINES

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recently, work with DNA/MVA HIV/AIDS vaccines has shown that GM-CSFcan enhance the presence of anti-viral IgA in the rectal secretions of immunized animals. One of the current challenges of vaccacinology is to elicit mucosal responses following parenteral administration of vaccines. To further explore the ability of GM-CSF to serve as a mucusal adjuvant, we studied the effect of co-administration of GM-CSF on the ability of inactivated polio vaccine to elicit mucosal responses. Comparing to oral polio virus vaccine, the inactivated polio vaccine elicits much less anti-viral IgA in rectal secretions. The goal of the project is to test whether GM-CSF can also enhance the presence of anti-viral IgA in rectal secretions for the inactivated polio vaccine. If sucessful, the studies will open a new approach for enhancing the mucosal responses elicited by the inactivated polio vaccine, a vaccine that is safer than the live-attenuated vaccine. The studies will also show whether GM-CSF can be used to enhance the ability of an parenteral vaccine to elicit mucosal responses. The polio vaccine will be used to vaccinate 12 rhesus macaques that were previously immunized with our DNA/MVA HIV/AIDS vaccine. Eight of these animals were intrarectally challenged with SHIV-162P3 in September of 2006. These challenged monkeys have controlled SHIV-162P3 to below our level of detection and have reconstituted their gut CD4 T cells.